Financials

News Ideas Discussions Technicals Forecast Seasonals

ALNFL fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

ALNFL has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company